Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3485253 | 0.94 | THRB (0.46) | THRBSMN1; SMN2LMNAKDM4EGAA | |
| SCHEMBL23881931 | 0.94 | THRB (0.46) | THRBSMN1; SMN2LMNAKDM4EGAA | |
| SCHEMBL5091076 | 0.86 | MTNR1A (0.37) | THRBCYP3A4 | |
| SCHEMBL5006986 | 0.86 | MTNR1A (0.37) | THRBCYP3A4 | |
| SCHEMBL5089466 | 0.86 | MTNR1A (0.37) | THRBCYP3A4 | |
| SCHEMBL3214409 | 0.78 | KDM4E (0.41) | THRBSMN1; SMN2KDM4EGAAEPHX1 | |
| SCHEMBL11275440 | 0.77 | MTNR1A (0.49) | THRBKDM4EGAAEPHX1ALDH1A1 | |
| SCHEMBL2634531 | 0.77 | — | — | |
| SCHEMBL13735251 | 0.76 | BTK (0.54) | THRBGAAEPHX1EPHX2KMT2A | |
| SCHEMBL24874466 | 0.76 | BTK (0.54) | THRBGAAEPHX1EPHX2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4328223-A2 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals, LLC (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-2699553-B1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20230116093-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2023-04-13 | — | — | US | disclosed |
| US-11325890-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2022-05-10 | — | — | US | disclosed |
| US-20210114992-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2021-04-22 | — | — | US | disclosed |
| US-10919865-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2021-02-16 | — | — | US | disclosed |
| US-10421760-B2 | Pyrrolo[2,3-d]pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-09-24 | — | — | US | disclosed |
| US-20190194144-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2019-06-27 | — | — | US | disclosed |
| US-10266500-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180305322-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2018-10-25 | — | — | US | disclosed |
| EP-3330271-A1 | PYRROLO[2,3-d]PYRIMIDINE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2018-06-06 | — | — | EP | disclosed |
| US-20170267647-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2017-09-21 | — | — | US | disclosed |
| US-9701643-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2017-07-11 | — | — | US | disclosed |
| US-20150336901-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2015-11-26 | — | — | US | disclosed |
| US-9139534-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2015-09-22 | — | — | US | disclosed |
| EP-2699553-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals, LLC (US) | 2014-02-26 | — | — | EP | disclosed |
| US-20130029987-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2013-01-31 | — | — | US | disclosed |
| WO-2012145569-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-10-26 | — | — | WO | disclosed |
| WO-2010024980-A1 | 4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-03-04 | — | — | WO | disclosed |
| US-20100056491-A1 | 4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10421760-B2 | Pyrrolo[2,3-d]pyrimidine compound or salt thereof | JAK3, IFNG, STAT1 | THRB 3999/4885SMN1; SMN2 3955/4885LMNA 4873/4885 |
| US-20130029987-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, HDGF, MAP3K1 | THRB 1955/4885SMN1; SMN2 3353/4885LMNA 1545/4885 |
| US-20230116093-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, HDGF, MAP3K1 | THRB 1955/4885SMN1; SMN2 3353/4885LMNA 1545/4885 |
| US-20150336901-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, HDGF, MAP3K1 | THRB 1955/4885SMN1; SMN2 3353/4885LMNA 1545/4885 |
| US-20210114992-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, HDGF, MAP3K1 | THRB 1955/4885SMN1; SMN2 3353/4885LMNA 1545/4885 |
| US-20190194144-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, HDGF, MAP3K1 | THRB 1955/4885SMN1; SMN2 3353/4885LMNA 1545/4885 |
| US-20180305322-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, HDGF, MAP3K1 | THRB 1955/4885SMN1; SMN2 3353/4885LMNA 1545/4885 |
| US-20100056491-A1 | 4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | HTR6, HTR4, HTR3B | THRB 613/4885SMN1; SMN2 4204/4885LMNA 3151/4885 |
| US-10266500-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | MAP3K2, HDGF, MAP3K1 | THRB 1955/4885SMN1; SMN2 3353/4885LMNA 1545/4885 |
| US-11325890-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | MAP3K2, HDGF, MAP3K1 | THRB 1955/4885SMN1; SMN2 3353/4885LMNA 1545/4885 |
| US-20170267647-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, HDGF, MAP3K1 | THRB 1955/4885SMN1; SMN2 3353/4885LMNA 1545/4885 |
| US-10919865-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | MAP3K2, HDGF, MAP3K1 | THRB 1955/4885SMN1; SMN2 3353/4885LMNA 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.